Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL
2 ビュー
• 07/14/23
0
0
埋め込む
administrator
加入者
In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント